Summary:
52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Qualified Participants Must:
• Have had Asthma for 2 years
•
Receiving treatment by Mepolizumab or Benralizumab
Qualified Participants May Receive:
-GSK3511294 (Depemokimab)